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Abstract
Purpose The purpose of this study was to report on the
clinical outcome of a large heterogenic cartilage repair
population treated with the profiling strategies of one
experienced cartilage surgeon to provide evidence based
tools for treatment selection in a clinical environment.
Methods A total of 216 patients were identified in this
prospective single-surgeon study. For the primary and
secondary treatment of smaller defects, microfracture (MF)
was used. Hyalograft C was used for first and second line
larger defects, while carbon-fiber rod and pad implanta-
tions were used as a salvage procedure.
Results Three years after the initial procedure, the clini-
cal improvement was excellent for MF and Hyalograft C
(P \ 0.001) and good for carbon-fiber procedures
(P \ 0.05). Hyalograft C patients with prior anterior cru-
ciate ligament reconstruction had less clinical improvement
(P \ 0.05), while MF patients with prior cartilage repair
were more likely to fail (Odds Ratio 20.5, P \ 0.05).
Conclusion This is the first study that provides an
assessment of the treatment strategies used by an experi-
enced cartilage surgeon. A treatment algorithm for carti-
lage repair in a heterogenic population was created that
based on the findings of this study could be implemented in
a clinical environment.
Level of evidence Prospective clinical case series, Level
IV
Keywords Cartilage repair  Patient profiling 
Experienced cartilage surgeon  Heterogenic population
Introduction
The steady increase in interest and availability of focal
articular cartilage repair techniques and the good long-term
results achieved during the last decade have increased the
heterogeneity of the patients requiring cartilage repair [5, 8,
39, 40]. That is, inclusion criteria for cartilage repair now
range from single defects in young and active patients to
early arthritic lesions in older (active) patients.
Although the focus on patient profiling has increased in
recent years, treatment selection is still largely based on the
preference of the surgeon and availability of different
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treatment types. Most surgeons agree that microfracture
(MF) is a good option for smaller defects, while autologous
chondrocyte implantation (ACI) is preferred for larger
lesions [3]. The clinical outcome seems dependent on the
patient’s age, level of activity, defect location and treat-
ment delay [3, 12, 19, 25, 43]. It is important to note that
these findings are based on studies that have excluded
certain patients, despite them being suitable for articular
cartilage repair procedures, as most (randomized) trials
have strict inclusion criteria such as a maximum age or
number of defects [1, 18, 21, 44, 48, 49]. Only a handful of
studies include salvage procedures for (young) patients
with early osteoarthritic lesions [29]. Moreover, it has been
shown that the methodological quality of studies in carti-
lage repair is generally low [20]. As such, there is a need
for an evidence based selection procedure to identify
patients suitable for focal cartilage repair.
The purpose of this prospective study was to analyze the
clinical outcome of patients following the application of
extensive profiling strategies, by an experienced cartilage
surgeon (MB), to a heterogenic group of patients suitable
for cartilage repair to provide evidence based tools for
treatment selection in a clinical environment.
Materials and Methods
Between 2006 and 2008, two hundred and sixteen patients
suitable for focal cartilage repair were followed in this
prospective study. The inclusion criteria for the study were:
traumatic or degenerative symptomatic full thickness grade
III to IV International Cartilage Repair Society lesions
(ICRS) [9, 35] on the femur, trochlea and patella. The most
important indicators for treatment were pain in rest and
motion and (occasional) locking of the joint. In addition, a
baseline Brittberg-Peterson VAS C 50 contributed
strongly to the decision for surgery. Patients were excluded
from the study if they had multiple defects in one knee that
were treated with different techniques, e.g. MF and ACI
and/or opening wedge osteotomy, symptomatic cartilage or
ligament injuries in both knees, widespread osteoarthritis,
inflammatory arhtritis and/or incomplete baseline ques-
tionnaires ([3 missing items per questionnaire). During the
initial screening, several patient characteristics such as age,
BMI, smoking, defect size, defect location, defect cause,
symptom to treatment delay and previous procedures, as
well as baseline outcome were recorded in a database. All
patients gave their informed consent prior to inclusion in
this study. A senior surgeon (MB) in a specialized cartilage
repair centre treated all patients.
Treatment strategy and surgical techniques
For the first and second line (subsequent to previous repair)
treatment of smaller defects (B2.5 cm2), MF as described
by Steadman was used [47]. Hyalograft C autografts [38]
were used for the first and second line treatment of larger
defects ([2.5 cm2) while carbon-fiber scaffold implanta-
tion was used as a salvage procedure for medium to large
(C1.5 cm2) early osteoarthritic (ICRS grade III–IV)
defects. In addition, MF and carbon-fiber scaffolds were
used for partial graft repair (i.e. repair of a failure of up to
one-third of a previous created autologous chondrocyte
graft). The Hyalograft C technique was preferred over MF
for patients with high (sport related) physical demands with
lesions 1.5–2 cm2 as well as patients with more than two
previous cartilage repair procedures. Figure 1 provides an
overview of the predefined treatment algorithm used in this
study.
After drilling down to the vascular subchondral bone,
woven carbon-fiber scaffolds were implanted as rods for
convex surfaces and pads for concave surfaces [4, 7, 27,
33]. A Hyalograft C implantation for all femoral and
trochlear defects was performed with arthroscopy, whereas
Fig. 1 Treatment algorithm
with pain, lesion type, defect
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mini-arthrotomy was used for patellar lesions. A treatment
was considered a failure if during a second look arthros-
copy, a patient needed a new repair procedure for at least
two-thirds of the cartilage defect.
Rehabilitation
All patients were weight bearing immediately after surgery,
walking with crutches for 4- to 6-weeks to the extent
allowed by an individual’s pain tolerance. Patients with
larger defects ([2 cm2) and all patients treated with
Hyalograft C received an additional knee brace that was
locked in extension for 2-weeks and unlocked for 4-weeks.
Each patient trained once to twice daily under supervision
of a specialized physiotherapist for 6-weeks and self-
training exercises were recommended for further 6-weeks.
Return to full activity was not permitted until at least
6-months post-operatively, depending on an individual’s
clinical improvement.
Outcome measurement
Patients were asked to complete four patient-based ques-
tionnaires: the Knee Injury and Osteoarthritis Outcome
Score (KOOS), the Brittberg-Peterson Visual Analogue
Scale (VAS), the Lysholm Knee Scoring Scale and a sub-
jective evaluation of clinical improvement (SECI) prior to
and 3 years after surgery. The KOOS was designed for the
follow-up of knee injury and osteoarthritis and has been
validated for the treatment of cartilage lesions [2, 3, 41]. A
modified version of the Lysholm scale has been validated to
assess cartilage damage [45]. The Brittberg-Peterson VAS
contains 13 items to measure different parameters of pain
and function, on a scale of 0–100, where a score of 100
indicates the worst outcome [39]. The SECI consisted of a
question regarding post-operative improvement (com-
pletely improved/much better/slightly improved/unchanged
or worse) [6].
Statistical analysis
Paired 2-tailed t tests were used to measure the improve-
ment from baseline scores for each treatment type.
Unpaired 2-tailed t tests were used to compare the clinical
outcomes between different treatment types.
For each separate treatment, as well as for all proce-
dures, multiple linear regression analysis with backward
elimination was used to determine prognostic factors that
influenced the clinical outcome. To identify what influence
the location of the defect had, the medial femoral condyle
and patella were compared to all other sites. The defect
cause was included in the analysis as either traumatic or
non-traumatic. To ensure valid inclusion in the regression
model, each patient’s characteristics were subjected to a
normality test using the Kolmogorov–Smirnov coefficient,
a test for inter-variable correlation with the Pearson cor-
relation coefficient and the variance inflation factor (VIF)
and a test for autocorrelation with the Durbin-Watson
coefficient. A VIF close to zero is considered indicative
for multicollinearity [10]. A Durbin-Watson coefficient
close to zero or four suggests strong negative and strong
positive autocorrelation respectively [13]. Characteristics
that were not normally distributed were excluded from the
regression analysis. To exclude a possible treatment-by-
covariate effect between the treatment types and the
patient characteristics, a Levene homogeneity test was
used. For each characteristic, the regression coefficient
(B) along with the P value and 95% confidence interval
(CI) was obtained. The B coefficient indicated the change
in clinical outcome score for the presence or alteration of
an included variable. Multiple logistic regression analysis
was used to identify risk factors for failure after treatment
and determine their separate odds ratios, along with the
P values and 95% CI’s [11]. Statistical analysis was per-
formed with SPSS 17.0. P values \ 0.05 were considered
statistically significant.
Results
Of the 216 patients, 86 patients were treated with MF, 71
with Hyalograft C and 59 with carbon-fiber scaffolds. For
MF, 10 patients had incomplete baseline questionnaires and
11 patients were lost to follow-up. For Hyalograft C, 17
patients were excluded (incomplete: n = 6, lost to follow-
up: n = 11). For carbon-fiber scaffolds, 12 patients were
excluded (incomplete: n = 2, lost to follow-up: n = 10).
From the resulting 166 patients, three separate cohorts were
obtained: 65 patients were treated with MF; 54 with
Hyalograft C and 47 with carbon-fiber scaffolds. Table 1
summarizes the demographics and baseline characteristics.
Clinical assessment
The average follow-up time for MF, Hyalograft C and
carbon-fiber scaffolds was 38 ± 5 months, 36 ± 8 months
and 36 ± 6 months, respectively. The baseline scores were
comparable for MF and Hyalograft C (n.s.) and slightly
(0–4 points) lower for carbon-fiber scaffolds (-8 points in
the Lysholm score (P = 0.003). (Table 1) Statistically
significant pre- to post-operative improvement was seen for
all scores of the MF and Hyalograft C groups. (P \ 0.001)
For carbon-fiber-scaffolds the clinical improvement was
good. (P \ 0.001–0.002) The improvement from baseline
was higher for both the MF and Hyalograft C cohorts,
compared to carbon-fiber scaffolds and statistically
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significant for the KOOS sports and QoL subscales.
(P \ 0.05) The clinical improvement for all scores and
subscales is shown in Table 2 and Fig. 2. The SECI score
was good with slight to complete improvement reported in
82% of MF procedures, 88% of Hyalograft C implantation
and 80% for carbon-fiber procedures respectively. For
all procedures, patients with anterior cruciate ligament
(ACL) reconstruction improved on the KOOS and VAS
(P \ 0.05) but did not show a significant improvement in
their Lysholm score (n.s.).
Linear regression analysis
Of the patient characteristics, smoking and treatment delay
had to be excluded from analysis due to failed normality
tests (n.s.). For the remaining variables, no multicollinearity
or autocorrelation was observed in any of the treatment
types (VIF 1.000–1.127, Durbin Watson 1.997–2.232). The
Levene tests of homogeneity of regression slopes were not
statistically significant (n.s.) indicating no treatment by
covariate interaction.
Table 1 Demographics and baseline characteristics
Characteristic Microfracture (n = 65) Hyalograft C (n = 54) Carbon fiber (n = 47)
Age (mean years ± SD) 40 ± 12 37 ± 9 47 ± 9
Men 54% 63% 62%
BMI (mean ± SD) 26.2 ± 4.3 25.3 ± 3.6 26.5 ± 5.5
Smoking (n) 10 5 7
Multiple defects (n) 16 25 16
Defect size (mean cm2 ± SD) 1.8 ± 1.5 3.9 ± 2.3 2.7 ± 1.9
Location: medial (n) 28 13 27
Lateral (n) 10 2 3
Trochlea (n) 8 6 2
Patella (n) 3 10 1
Femur and trochlea (n) 12 14 12
Femur and patella (n) 3 3 1
Trochlea and patella (n) 1 6 1
Sports-related injury 65% 52% 68%
Treatment delay (months ± SD) 97 ± 100 79 ± 62 100 ± 85
Second line treatment 35% 41% 72%
Diagnostic arthroscopy (n) 42 23 13
Previous treatment microfracture (n) 12 13 7
Previous treatment carbon fibers (n) 5 3 19
Previous treatment ACI (n) 6 6 8
Prior ACL reconstruction (n) 7 11 6
Time from ACL reconstructiona (months) 66 ± 89 51 ± 48 144 ± 36
Baseline VAS (mean ± SD) 51.9 ± 19.4 56.1 ± 19.7 55.5 ± 18.1
Baseline overall KOOS (mean ± SD) 47.8 ± 15.4 46.3 ± 17.6 45.2 ± 17.2
Baseline Lysholmb 52.5 ± 18.2 51.6 ± 21.8 44.3 ± 18.6
Partial menisectomy (n) 20 10 18
Total menisectomy (n) 5 7 2
Partial (1/3) graft repair (n) 10 0 18
Opening wedge osteotomy (n) 5 5 7
Follow up (months ± SD) 34.0 ± 5 30.0 ± 8 32.0 ± 6
Failures (n) 8 8 7
Time to treatment failure (months ± SD) 17.0 ± 6.8 10.6 ± 4.7 17.1 ± 4.8
ACL anterior cruciate ligament, VAS Brittberg Petersson visual analogue scale, KOOS knee injury and osteoarthritis outcome score
a Time between ACL reconstruction and cartilage repair
b Tegner Lysholm Knee Scoring Scale
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Patient age, BMI, defect cause and defect size did not
seem to influence clinical outcome (n.s.). Patellar and
medial lesions did not significantly differ in outcome
scores compared to other defect locations for any of the
treatment groups (n.s.).
In the MF cohort, patients with partial (1/3) graft repairs
scored 24–32 points less improvement from baseline
(regression coefficient (B) -24.0 to -32.4) on KOOS Pain,
Sports and QoL subdomains (P \ 0.05), while partial graft
repairs did not reduce clinical outcome in the carbon-fiber
group (n.s.).
For Hyalograft C, patients with prior ACL reconstruc-
tion had reduced improvement from baseline compared to
patients without prior ACL reconstruction. (VAS B -20.6,
overall KOOS B -13.4, Lysholm B -19.8, P =
0.006–0.042). In all patients, single defects scored 13.0, 8.4
and 8.1 points higher on KOOS Sports and QoL and
Lysholm scale respectively when compared to multiple
defects (P \ 0.05).
Failures
In both the MF and Hyalograft C cohort there were 8
failures while there were 7 failures in the carbon-fiber
group. (Table 1) Of all failures 91% occurred within
2-years and 35% within 1-year. Patients with prior cartilage
Table 2 Mean improvement from baseline in the Knee Injury and Osteoarthritis Outcome Score (KOOS), Brittberg-Peterson Visual Analogue
Scale (VAS) and Lysholm Knee Scoring Scale 3 years after surgery
Outcome scores Microfracture Hyalograft C Carbon fiber
Score ± SD P value Score ± SD P value Score ± SD P value
VAS 19 ± 33 \ 0.001 25 ± 26 \ 0.001 17 ± 18 \ 0.001
KOOS Symptoms 20 ± 21 \ 0.001 17 ± 23 \ 0.001 12 ± 24 0.003
KOOS Pain 23 ± 23 \ 0.001 23 ± 26 \ 0.001 12 ± 21 0.001
KOOS ADL 19 ± 20 \ 0.001 19 ± 23 \ 0.001 10 ± 20 0.004
KOOS Sports 22 ± 29 \ 0.001 18 ± 26 \ 0.001 9 ± 31 n.s.
KOOS QoL 22 ± 24 \ 0.001 23 ± 25 \ 0.001 13 ± 23 0.001
KOOS Total 21 ± 20 \ 0.001 20 ± 21 \ 0.001 11 ± 20 0.002
Lysholm 15 ± 22 \ 0.001 18 ± 24 \ 0.001 13 ± 18 \ 0.001
SD standard deviation
Fig. 2 Mean improvement
from baseline and 95%
Confidence intervals for the
knee injury and osteoarthritis
outcome Score (KOOS), the
Brittberg-Peterson visual
analogue scale (VAS) and the
Lysholm Knee Scoring Scale
3 years after surgery
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repair treated with MF were more likely to fail (Odds Ratio
20.5, 95% confidence interval 3.4–33.2, P = 0.003).
Discussion
The most important finding of the present study was that
excellent clinical outcome was obtained using the patient
profiling strategies of one experienced cartilage surgeon
(MB) in a heterogenic population with chondral/osteo-
chondral as well as early osteoarhtritic lesions. As such, it
supports the use of the predefined treatment algorithm in a
clinical environment (Fig. 1).
Although Hyalograft C was generally used for larger
lesions, highly statistically significant clinical improvement
after 3-years was achieved for both the MF and Hyalograft
C cohorts. (Table 2) This high clinical improvement is
similar to 3-year results from randomized and non-ran-
domized studies of patients treated with cartilage repair
[21, 26, 31, 43]. As pain relief was considered one of the
primary goals of treatment, the statistically significant
improvement (P \ 0.001) on the VAS and KOOS pain
subscale for each separate group (Table 2) further under-
lines the effectiveness of the current profiling strategies.
Even though Hyalograft C was used more often in active
patients, the improvement of the KOOS sports subscale was
comparable with MF after 3 years. However, long-term
results might be more indicative for these patients as
Hyalograft C has been found to have similar clinical and
sports related outcome compared to MF after 2-years while
achieving a superior clinical (sport related) outcome after
5-years [23]. The higher histomorphometric and histologic
scores previously demonstrated in ACI compared to MF, in
addition to a higher and more durable return to sports found
in athletes, further support our treatment algorithm, in which
Hyalograft C is preferred for more active patients [30, 44].
In a prospective case series, Filardo et al. [15] found
second-generation ACI to achieve a lower clinical
improvement if patients underwent previous surgeries such
as menisectomy, ACL reconstruction, MF or mosaicplasty.
This was corroborated in our Hyalograft C cohort, where
patients with a prior ACL reconstruction exhibited a sig-
nificantly lower clinical improvement from baseline. One
explanation could be a disturbed joint homeostasis, that is
to say that remaining instability and/or inflammation may
disturb cartilage regeneration [42]. Moreover, the previ-
ously illustrated increased odds ratio of cartilage degrada-
tion after ACL rupture might continue even after
reconstruction [17]. This emphasises the need for further
research aiming at improving clinical outcome of patients
with ACL ruptures and (subsequent) cartilage damage.
Similarly to Filardo, Minas et al. [28] showed an increased
failure rate of first generation ACI after marrow stimulating
techniques. Although we did find a higher failure rate for
MF as second line treatment, this did not occur in the
Hyalograft C and carbon-fiber group. In the above-men-
tioned reports, a predefined treatment algorithm could not
be identified. In addition, Filardo et al. [30] applied carti-
lage repair by surgeons in different centres. Therefore,
careful patient selection and treatment by one senior sur-
geon following a predefined treatment algorithm, may
improve treatment results. This approach could explain the
superior clinical outcome we achieved for patients
receiving second line cartilage repair.
In the current study, carbon-fiber scaffold implantation
resulted in overall lower clinical improvement than the
other two cohorts. However, carbon-fiber scaffolfds were
used for a separate cohort with early osteoarthritic lesions
and demonstrated a high statistically significant improve-
ment in the VAS, KOOS Pain and Lysholm score
(P \ 0.001). Surprisingly, Nehrer et al. [32] did not find a
significant improvement in Lysholm for a similar salvage
group with Hyalograft C after 3-years. Taking the above
into account, this study demonstrates that carbon-fibers are
useful for salvage repair and supports the treatment of this
patient category.
MF and carbon-fiber implantation were also used for
partial graft repair. As MF resulted in a significantly
reduced clinical improvement in these patients, carbon-
fibers seem to be a better option for this group as well.
Nevertheless, further studies are needed to correctly iden-
tify risk factors for partial failures and improve the clinical
outcome, as evidence for treatment of this challenging
group is lacking in current literature.
With regard to the patient characteristics, patient age did
not influence clinical outcome. This finding might be
attributable to the careful treatment selection of the surgeon
(MB) as older patients are more likely to have early osteo-
arthritic lesions and receive carbon-fiber implants. However,
as no affect of age was found after correcting for treatment
type, the previously illustrated influence of this variable
should be considered together with other characteristics such
as (sports) activity and overall health as well [12, 18, 21, 24,
25, 34]. Moreover, our findings are similar to a 2-year follow-
up study showing no difference in clinical outcome after ACI
for patients 40 years and older compared to younger patients
[34]. In addition, good clinical results have recently been
demonstrated after 2- to 5-years in patients 40 years and
older after second-generation ACI [22].
In recent years, medial as well as lateral lesions have
been shown to have better clinical outcome while patellar
lesions have been reported to be more challenging to
repair, possibly due to greater biomechanical shearing
forces [12, 25, 36, 37]. However, when comparing medial
and patellar lesions to other sites, we found no statistically
significant difference in outcome scores. This is in
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accordance with a previous study demonstrating similar
statistically significant (P \ 0.001) improvement in clini-
cal outcome after treatment of patellofemoral lesions
(mean size 4.7 cm2) treated with Hyalograft C [16].
Regardless of treatment type, multiple defects resulted
in lower clinical improvement compared to single defects.
Similarly, Solheim et al. [46] found inferior clinical out-
come for MF of multiple versus single defects. Although
these patients seem to benefit of cartilage repair as shown
by improved outcome scores, multiple defects should be
regarded as a separate, more difficult patient population.
Limitations of this study could be that it lacks ran-
domization, includes different locations in the knee with a
variety of defect etiologies and did not include a control
group. However, we stress that the primary goal of this
observational prospective study was not to demonstrate
superiority of one particular treatment but to evaluate the
clinical outcome of a heterogenic patient population after
treatment of one experienced surgeon (MB) according to a
predefined selection algorithm. Moreover, the indications
of the cartilage repair procedures do not overlap, which
may emphasize why randomization in this patient category
is difficult and why previous randomized trials do not
include all patients suitable for cartilage repair [14, 20].
The strengths of this study lie in the treatment of a rela-
tively large group of patients and the inclusion of a wide
range of patients suitable for cartilage repair in different
cohorts. Unlike most cartilage repair reports, where data
are published based on multi-surgeon and/or centre studies,
this study focused on a single senior surgeon in one spe-
cialized cartilage repair centre.
Conclusion
To the best of our knowledge, this is the first assessment of
the treatment strategies used by one experienced cartilage
surgeon based on lesion and patient characteristics. We
provide a treatment algorithm with pain, lesion type, defect
size and patient activity as indicators for treatment selec-
tion (Fig. 1). Our data suggest Hyalograft C to be a good
second line treatment option and support the treatment of
early osteoarthritic lesions. The treatment algorithm and
new insights of this single-surgeon study could be used for
patient profiling in a day-to-day clinical environment.
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